Full text
Earnings transcript
Read the complete earnings call transcript.
OSUR
OraSure Technologies, Inc.
$4.24
0.09
(2.17%)
| Exchange: | NASDAQ |
| Market Cap: | 291.918M |
| Shares Outstanding: | 8.387M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Carrie Eglinton Manner | |||||
| Full Time Employees: | 501 | |||||
| Address: |
| |||||
| Website: | https://www.orasure.com |
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure’s sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 405,472 | 185,827 | 115,021 |
| Gross Profit | 179,421 | 76,227 | 48,198 |
| EBITDA | 73,979 | -9,728 | -58,154 |
| Operating Income | 54,079 | -20,600 | -68,124 |
| Net Income | 53,655 | -19,500 | -68,731 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 482,845 | 479,659 | 403,168 |
| Total Liabilities | 52,174 | 69,321 | 62,341 |
| Total Stockholders Equity | 430,671 | 410,338 | 340,827 |
| Total Debt | 13,504 | 14,604 | 13,197 |
| Cash and Cash Equivalents | 290,407 | 267,763 | 199.278 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 141,583 | 27,374 | -49.023 |
| Capital Expenditure | -10,303 | -3,797 | -4.197 |
| Free Cash Flow | 131,280 | 23,577 | -53.220 |
| Net Income | 53,655 | -19,500 | -68.731 |
| Net Change in Cash | 206,427 | -22,644 | -68.485 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 129,517.817 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 129,517.819 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 129,517.818 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -9,140.186 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -9,140.185 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -9,140.185 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -7,441.826 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -7,254.983 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -7,348.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 50,992.258 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 50,992.259 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 50,992.259 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.100 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.100 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.100 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates OSUR intrinsic value between $4.66 – $4.78 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about OSUR valuation
Is OraSure Technologies, Inc. (OSUR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for OraSure Technologies, Inc. (OSUR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is OSUR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OSUR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is OSUR’s P/E ratio?
You can see OSUR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for OSUR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is OSUR a good long-term investment?
Whether OSUR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
OSUR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.17
Trading Metrics:
| Open: | 4.18 | Previous Close: | 4.15 | |
| Day Low: | 4.12 | Day High: | 4.27 | |
| Year Low: | 2.08 | Year High: | 4.33 | |
| Price Avg 50: | 3.27 | Price Avg 200: | 2.94 | |
| Volume: | 734677 | Average Volume: | 596388 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
